臺灣博碩士論文加值系統

中文摘要

研究目的：本研究想知道在台灣新診斷的第二型糖尿病患，醫師第一個使用的降血糖用藥為何以及其病患特性像是年齡、性別、就醫層級、就醫科別。
研究方法：利用健保資料庫2010年的世代資料。收納為2010年新發病且有使用降血糖用藥的第二型糖尿病患者，利用描述性統計分析第一線用藥處方和病患特質。
研究結果：台灣對於新發病的第二型糖尿病且第一次就診只使用一種口服降血糖藥物病人為3830位在降血糖藥物選擇分別metformin 59%、sulfonylurea 30%、thiazolidinedione 5%、acarbose 3%、dipeptidyl peptidase-4 inhibitors 2%、meglitinide 2%。Metformin為主要第一線用藥。新診斷病患就醫科別以家醫科、新陳代謝科、其他科(包含心臟科、腎臟科、一般內科、外科分等等)別為19%、24%、57%。可以發現新陳代謝科開立metformin比率最高，sulfonylurea則以家醫科開立比率最高。


關鍵字：第二型糖尿病、糖尿病用藥、健保資料庫

Abstract
Background: Diabetes is an increasing global health problem. For maintaining optimal glycemic level of patients with Type 2 diabetes(T2D), various classes of glucose-lowing drugs are used. The mechanisms of each class is different from each other.
Objective: The purpose of the study was to analyze the first anti-diabetic drugs medicinal for newly diagnosed type 2 diabetes patients and their characteristics including age, sex, and hospital level.
Methods: Data of T2D in the study were from the Taiwan National Health Insurance Database in 2010. The main classes of glucose-lowing drugs included acarbose, metformin, sulfonylureas, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, and meglitinide.
Results: Of the 3830 patients analyzed, metformin was prescribed 59%,
followed by 30%, sulfonylurea, 5% thiazolidinedione, 3% acarbose, 2% Dipeptidyl peptidase-4 inhibitors,and 2% meglitinide, as their first monotherapy. Metformin was mainly prescribed by endocrinologists and sulfonylurea was first considered by family physicians. Over half of the patients (57%) receiving their prescriptions from physicians with the specialty of general medicine, 24% family medicine, and 19% from endocrinology.
Conclusions: The results of this study provide insight from national prospective regarding medications and the treatment characteristics to better understand the drug pattern for the newly diagnosed T2D patients.
Key words: type 2 diabetes mellitus, drug pattern, anti-diabetic drug

目 錄
致謝................................................... I
中文摘要...............................................II
Abstract..............................................III
目錄...................................................IV
圖目錄.................................................VI
表目綠................................................VII
第一章 緒論.............................................1
第一節 研究背景與動機 ................................. 1
第二節 研究問題與目的 ................................ .3
第二章 研究方法.........................................4
第一節 研究設計和研究架構.............................. 4
第二節 研究設計 ................................ ...... 5
第三節 資料處理與流程 ................................. 7
第四節 資料來源與研究對象 ............................. 8
第五節 統計分析 ................................ ..... 10
第六節 研究目的 ................................ ..... 10
第三章 研究結果........................................12
第一節 台灣2010年新診斷第二型糖尿病人討論 ........... .12
第二節 台灣新診斷初第二型糖尿病人與美國用藥比較 ...... 16
第四章 研究結果 ................................ ......18
第五章 建議............................................20
參考文獻...............................................21

1.WHO. Global Tuberculosis report 2012: World Health Organisation; 2012.
2.Mei-Shu Lai,National health insurance and the way leading to better diabetes care in Taiwan. Is there a role of comprehensive analyses of the claims data? JFMA 2012, 111(11): 587-588
3.Yi-Der Jiang, Chia-Hsuin Chang, Tong-Yuan Tai, Jung-Fu Chen, Lee-Ming Chuang,Incidence and prevalence rates of diabetes mellitus in Taiwan: Analysis of the 2000–2009 Nationwide Health Insurance database JFMA 2012, 111(11): 599-604
4.Tien-Jyun Chang, Yi-Der Jiang, Chia-Hsiun Chang, Ching-Hu Chung, Neng-Chun Yu, Lee-Ming Chuang,Accountability, utilization and providers for diabetes management in Taiwan, 2000–2009: An analysis of the National Health Insurance database .JFMA 2012, 111(11): p605–616
5.Chia-Hsuin Chang, Yi-Der Jiang, Ching-Hu Chung, Low-Tone Ho, Lee-Ming Chuang,National trends in anti-diabetic treatment in Taiwan, 2000–2009. JFMA 2012, 111(11):p617–624
6.Li-Nien Tseng, Yao-Hsien Tseng, Yi-Der Jiang, Chia-Hsuin Chang, Ching-Hu Chung, Boniface J. Lin, Lee-Ming Chuang, Tong-Yuan Tai, Wayne H.-H. Sheu,Prevalence of hypertension and dyslipidemia and their associations with micro- and macrovascular diseases in patients with diabetes in Taiwan: An analysis of nationwide data for 2000–2009.JFMA 2012, 111(11):p625–636
7.Ching-Hu Chung, Lee-Ming Chuang, Tong-Yuan Tai, Low-Tone Ho, Shyi-Jang Shin, Yu-Yao Huang, Kun-Der Lin, Yi-Der Jiang, Chia-Hsuin Chang,Diabetes-related kidney, eye, and foot disease in Taiwan: An analysis of the nationwide data for 2000–2009.JFMA 2012, 111(11):p637–644
8.2015<糖尿病臨床照護指引摘要>,社團法人中華民國糖尿病學會
9.2010<美國糖尿病照護指引>
10.2012年台灣糖尿病核心教材
11.UKPDS 35, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405
12.國民健康署2013-2015年「國民營養健康狀況變遷調查」
13.蔡世澤,2004,中華民國糖尿病衛教學會
14.Seth A. Berkowitz, MD, MPH; Alexis A. Krumme, MS; Jerry Avorn, MD; Troyen Brennan, MD, MPH, JD;Olga S. Matlin, PhD; Claire M. Spettell, PhD; Edmund J. Pezalla, MD, MPH; Gregory Brill, MS;William H. Shrank, MD, MSHS; Niteesh K. Choudhry, MD, PhD Initial Choice of Oral Glucose-Lowering Medication for Diabetes Mellitus A Patient-Centered Comparative Effectiveness Study. JAMA Intern Med. 2014 Dec;174(12):1955-62. doi: 10.1001
15.Brien Rex Miller, DO, Hanh Nguyen, DO, Charles Jia-Haur Hu, DO, Chihyi Lin, DO, and Quang T. Nguyen, DO, FACP, FACE, FTOS New and Emerging Drugs and Targets for Type 2 Diabetes: Reviewing the Evidenc.Am Health Drug Benefits. 2014 Nov; 7(8): 452–463.
16. Christianne L. Roumie, MD, MPH; Adriana M. Hung, MD, MPH; Robert A. Greevy, PhD; Carlos G. Grijalva, MD, MPH; Xulei Liu, MD, MS; Harvey J. Murff, MD, MPH; Tom A. Elasy, MD, MPH; and Marie R. Griffin, MD, MPH .
Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus A Cohort Study.2012 Annals of Internal Medicine Volume 157 Number 9 :601-609